Article citationsMore>>

I. Puzanov, J. A. Sosman, A. Santoro, R. E. Martell, G. K. Dy, L. Williams Goff, W. W. Ma, G. J. Fetterly, S. A. Michael, J. A. Means-Powell, F. Chai, M. Lamar, G. M. Strauss, P. A. Zucali, W. M. Chiang, J. Jarboe, B. E. Schwartz and A. A. Adjei, “Safety and Efficacy of MET Inhibitor Tivantinib (ARQ 197) Combined with Sorafenib in Patients (pts) with Renal Cell Carcinoma (RCC) from a Phase I Study,” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 4545.

has been cited by the following article:

• TITLE: Systemic Therapy of Advanced Renal Cell Carcinoma—Summary of Main Presentations at the ASCO, ASCO-GU and ESMO 2012 Annual Meetings

  AUTHORS: Andres Jan Schrader

  KEYWORDS: Renal Cell Carcinoma; ASCO; ESMO; Review; Systemic Therapy

  JOURNAL NAME: Open Journal of Urology, Vol.3 No.1, February 25, 2013

  ABSTRACT: A number of very interesting studies presented this year at the ASCO (American Society of Clinical Oncology) Annual Meeting, the ASCO-GU (ASCO Genitourinary Cancers) Spring Meeting, and the ESMO (European Society for Medical Oncology) Annual Congress could strongly influence or even revolutionize the systemic treatment of advanced renal cell carcinoma (RCC). The aim of this article is to identify, summarize and discuss some outstanding studies of direct or indirect clinical relevance for systemic therapy.